Selective CXCR4 binding peptide conjugate and methods for making and using the same
The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA 1 , AA 2 , Ar 1 , X 1 , and AA 3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders. Compositions, kits and methods are also disclosed herein for such uses.
1. A selective CXCR4 binding peptide conjugate (“PC”) of the formula:
or a pharmaceutically acceptable salt thereof,
wherein:
a is 0 or 1;
b is an integer from 1 to 4;
AA 1 along with the sulfur atom that is attached thereto is 3-mercaptopropionic acid, optionally substituted cysteine, optionally substituted homocysteine, or optionally substituted penicillamine;
AA 2 along with the sulfur atom that is attached thereto is cysteine or homocysteine;
Ar 1 is an optionally substituted aryl;
X 1 is Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), or Lys(iPr);
each of AA 3 is independently Gly, Phe, 2Nal, 1Nal, Arg, Dap, Dab, Orn, Lys, Dap(iPr), Dab(iPr), Orn(iPr), Lys(iPr);
and wherein at least one of AA 1 , X 1 , AA 2 , or AA 3 comprises a moiety of the formula:
-L 1 -Q,
wherein
L 1 is a polymeric linker having a functional group for linking Q, wherein L 1 comprises from about 2 to about 20 monomers or copolymers;
Q is absent, AA 4 , or a moiety of the formula: -[AA 4 -Y 1 -L 2 ] c -Y 2 -Z,
wherein
c is 0 or 1;
AA 4 is an amino acid or a derivative thereof;
Y 1 is a side-chain function group of amino acid AA 4 ;
L 2 is a non-polymeric linker;
Z a medically useful compound; and
Y 2 is a functional group of said medically useful compound or a functional group of L 2 ;
and wherein one or more of AA 1 , AA 2 , X 1 , AA 3 , and AA 4 are optionally isotopically labelled.
2. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein said medically useful compound comprises an imaging agent, a contrast agent, or a therapeutic agent.
3. The selective CXCR4 binding peptide conjugate according to claim 1 of the formula:
wherein a, b, AA 1 , X 1 , AA 2 , AA 3 , L 1 , Q, and Ar 1 are as defined in claim 1 .
4. The selective CXCR4 binding peptide conjugate according to claim 3 , wherein Q is absent.
5. The selective CXCR4 binding peptide conjugate according to claim 3 , wherein Q is AA 4 , or a moiety of the formula: -[AA 4 -Y 1 -L 2 ] c -Y 2 -Z.
6. The selective CXCR4 binding peptide conjugate according to claim 5 , wherein a is 0.
7. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein a is 0.
8. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein AA 1 is homocysteine.
9. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein a is 1.
10. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein X 1 is isotopically labelled.
11. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein AA 3 is isotopically labelled.
12. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein at least one of X 1 and AA 3 is isotopic labelled, and wherein said isotopically label comprises deuterium, tritium, 13 C, 14 C, 18 O, or a combination thereof.
13. The selective CXCR4 binding peptide conjugate according to claim 12 , wherein at least one of X 1 and AA 3 is isotopically labeled with deuterium or tritium.
14. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein said medically useful compound is a therapeutic agent.
15. The selective CXCR4 binding peptide conjugate according to claim 14 , wherein said therapeutic agent is an anticancer agent.
16. The selective CXCR4 binding peptide conjugate according to claim 15 , wherein said anticancer agent is selected from the group consisting of paclitaxel, Altretamine, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Diethylstilbestrol, Eribulin, Ethinyl, estradiol, Etoposide, Mitomycin, Mitotane, Mitoxantrone, Pentastatin, Pipobroman, Plicamycin, Prednisone, Procarbazine, Streptozocin, Tamoxifen, Teniposide, Vinblastine, and Vincristine.
17. The selective CXCR4 binding peptide conjugate according to claim 1 of the formula:
wherein a, b, AA 1 , X 1 , AA 2 , AA 3 , AA 4 , Y 1 , Y 2 , L 2 , Z, and Ar 1 are as defined in claim 1 ; and L 1a is a polymeric linker comprising from about 2 to about 20 monomers or copolymers.
18. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein L 2 is a non-polymeric linker of the formula: —CH 2 —C(═O)—NH—CH 2 —, —CH 2 —NH—C(═O)—CH 2 —, —(CH 2 ) n —C(═O)—NH—CH 2 —, —(CH 2 ) n —NH—C(═O)—CH 2 —, or —(CH 2 ) n —, wherein n is an integer from 1 to 6.
19. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein AA 1 along with the sulfur atom that is attached thereto is optionally substituted cysteine.
20. The selective CXCR4 binding peptide conjugate according to claim 19 , wherein α-amino group of AA 1 is substituted with an acetyl group.
21. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein AA 2 along with the sulfur atom that is attached thereto is optionally substituted cysteine.
22. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein X 1 is Lys(iPr) or Lys(deuterated-iPr).
23. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein AA 3 is Lys(iPr) or Lys(deuterated-iPr).
24. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein Ar 1 is phenyl.
25. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein b is 1.
26. The selective CXCR4 binding peptide conjugate according to claim 25 , wherein AA 3 is Lys(iPr) or Lys(deuterated-iPr).
27. The selective CXCR4 binding peptide conjugate according to claim 26 , wherein L 1 is a polymeric linker of the formula: —NH—(CH 2 ) 2 —[O—CH 2 —CH 2 ] n —O—(CH 2 ) 2 —C(═O)—, wherein n is an integer from 2 to 20, —NH— is attached to the carbonyl carbon of amino acid AA 3 , and —C(═O)— is attached to α-amino functional group of amino acid AA 4 .
28. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein AA 4 is cysteine, homocysteine, or penicillamine.
29. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein at least one of AA 1 , X 1 , AA 2 , or AA 3 amino acid residue is a (D)-isomer.
30. The selective CXCR4 binding peptide conjugate according to claim 1 , wherein said selective CXCR4 binding peptide conjugate is selected from the group consisting of Compound A, Compound B, Compound C, Compound D, Compound E, Compound F, Compound G, Compound H, Compound I, Compound J, Compound K, Compound L, Compound M, Compound N, Compound O, Compound P, corresponding deuterium labelled compounds thereof, and corresponding tritium labelled compounds thereof.
31. A method for treating a subject suffering from a cancer, said method comprising administering to the subject a therapeutically effective amount of a selective CXCR4 binding peptide conjugate of claim 1 , wherein said medically useful compound is an anticancer agent.
32. The method of claim 31 , wherein said anticancer agent is selected from the group consisting of paclitaxel, Altretamine, Asparaginase, Bleomycin, Busulfan, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Diethylstilbestrol, Eribulin, Ethinyl, estradiol, Etoposide, Mitomycin, Mitotane, Mitoxantrone, Pentastatin, Pipobroman, Plicamycin, Prednisone, Procarbazine, Streptozocin, Tamoxifen, Teniposide, Vinblastine, and Vincristine.
33. The method of claim 31 , wherein said cancer is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, kidney cancer, brain cancer, blood cancer, leukemia, prostate cancer, ovarian cancer, and bladder cancer.